SINGAPORE - German biotechnology company BioNTech SE said Monday it has chosen Singapore for its first regional hub in the Asia-Pacific region and will also set up a manufacturing facility in the city-state to produce mRNA-based vaccines.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
